10x Genomics, Inc. (NASDAQ: TXG)

$21.63 ▲ +0.56 (+2.63%)
As of May 14, 2026 12:18 PM
Sector: Healthcare Industry: Health Information Services CIK: 0001770787
Market Cap 2.62 Bn
P/E -60.00
P/S 4.08
Div. Yield 0.00
ROIC (Qtr) 0.00
Revenue Growth (1y) (Qtr) -2.61
Add ratio to table...

About

10x Genomics, Inc. is a life sciences technology company that develops instruments, consumables and software to enable high resolution and large scale biological analysis. The company’s mission is to accelerate the mastery of biology to advance human health. Its product portfolio includes the Chromium single cell platform, the Visium and Xenium spatial platforms and a suite of analysis software. The company generates revenue primarily from the sale of its instruments, consumable reagents and software licenses. For the fiscal year ended December...

Read more

Investment thesis

Bull case

  • 10x Genomics has demonstrated a consistent, double‑digit expansion in consumables revenue, with single‑cell and spatial divisions each reporting volume growth that outpaces price erosion. The introduction of FLEX APEX, a low‑cost, high‑throughput assay, has already triggered a 30 % surge in reaction volume within the first quarter, signalling that the market is only beginning to exploit the full potential of the platform. This early adoption phase, coupled with the company’s rapid roll‑out of new assays across multiple modalities, positions 10x to capture a growing share of the emerging AI‑driven biology space, where data volume is a primary competitive lever. {bullet} The spatial portfolio, particularly the Xenium system, is undergoing a decisive shift from a niche niche to a mainstream driver. Xenium’s expansion has contributed 14,500 new reactions in 2025, an increase of 34 % over the previous year, and the company’s sales force is actively extending the platform to new research and clinical sites. This momentum, combined with the company’s commitment to maintain the high utilization rates it has achieved, suggests that Xenium can continue delivering double‑digit revenue growth in 2026 and beyond, reinforcing 10x’s position as the de‑facto standard for spatial analysis. {bullet} Beyond the core life‑science customer base, 10x is building a new, high‑margin clinical evidence program through its CLIA laboratory. By leveraging existing infrastructure and intellectual property, the company can transition single‑cell and spatial assays into regulated diagnostics with a lower incremental cost than would be required for a traditional lab. Even if the capital outlay to build the lab is modest, the potential to generate a new revenue stream from diagnostic tests—particularly in oncology and autoimmune disease—provides a compelling upside that is not reflected in current financial projections. {bullet} The company’s balance sheet strength is a catalyst that supports accelerated innovation and strategic acquisitions. Cash, cash equivalents, and marketable securities climbed to $523 million year‑end, a $130 million increase over 2024, giving 10x the flexibility to pursue high‑impact partnerships, such as the recent collaborations with the Chan Zuckerberg Initiative and the Arc Institute. These alliances supply both data and financial support, while validating 10x’s technology in high‑profile, large‑scale projects that can generate spill‑over effects across the broader genomics ecosystem. {bullet} 10x’s product roadmap aligns with the structural shift toward data‑centric biology, where machine‑learning models require vast, high‑quality datasets. By positioning FLEX APEX as the premier platform for perturb‑seq and virtual cell experiments, the company is effectively creating a moat around a critical data‑generation niche that competitors will find costly to replicate. The company’s emphasis on modular assay design, compatibility with FFPE and whole‑blood specimens, and scalable throughput uniquely address the pain points of academic, industry, and clinical laboratories alike, creating a sustainable competitive advantage that can be leveraged for pricing power over time. {bullet} The firm’s aggressive cost management—evidenced by an 18 % drop in operating expenses during Q4 and a 1 % margin improvement to 68 %—provides a cushion to absorb the inevitable cap‑ex headwinds that will persist into 2026. By continuing to drive efficiencies in manufacturing, inventory write‑downs, and royalty obligations, 10x can preserve margin expansion even as it ramps consumables volume. This operational discipline signals to investors that the company can scale responsibly, mitigating the risk of margin compression from the ongoing reduction in instrument revenue. {bullet} Geographic diversification is providing resilience against U.S. research‑funding volatility. While Americas revenue slipped 6 %, EMEA and APAC experienced growth rates of 79 % and 79 % respectively, driven by late‑quarter institutional spend and robust demand for Xenium. This expansion into high‑growth markets suggests that the company is less exposed to a single funding source and can capitalize on regional differences in funding cycles, regulatory approvals, and customer maturity. Consequently, any future contraction in U.S. funding is unlikely to materially derail overall growth. {bullet} 10x’s ongoing participation in large, multi‑year projects—such as the “billion‑cell” initiative—provides a predictable, long‑term consumption pipeline. These projects are not only high‑profile but also create a network effect, as participating institutions adopt 10x instruments and consumables as their default platform, embedding the company deep into the research workflow. This can lead to incremental revenue from consumables that is more stable and less sensitive to short‑term budget swings than the instrument side of the business. {bullet} The company’s strategic focus on translational research aligns with industry trends toward biomarker discovery and precision medicine. As biopharma invests more heavily in patient‑centric studies, 10x’s single‑cell and spatial capabilities position it to supply the high‑resolution data needed to refine therapeutic windows, reduce attrition rates, and accelerate clinical development. Even if the current contribution from biopharma to revenue remains modest, the trajectory is upward and can potentially account for a sizable share of future earnings once these programs mature. {bullet} Finally, the timing of 10x’s guidance reinstatement—forecasting 0‑4 % revenue growth in 2026—reflects a conservative stance in a highly uncertain macro environment. This cautious outlook leaves ample upside room for any acceleration in consumables volume, new product adoption, or early diagnostics revenue. Investors who interpret the guidance as a floor rather than a ceiling stand to benefit from a potential upside that is not currently priced into the market.
Read more

Bear case

  • 10x Genomics continues to face a severe cap‑ex constraint that has already depressed instrument revenue by 36 % in Q4 and is projected to persist through 2026. The company’s guidance explicitly acknowledges that instrument demand will remain constrained, implying that consumables growth must offset any revenue shortfall from the hardware side. Given the high cost of instrument sales and the low elasticity of capital purchases in a research‑budget‑tight environment, sustained instrument revenue decline could erode gross margins and put pressure on operating leverage if consumables growth does not accelerate at a commensurate pace. {bullet} The firm’s most recent product launch, FLEX APEX, introduces a price/mix headwind that management is already monitoring closely. As customers transition from higher‑priced assays to the new lower‑cost platform, the average selling price per sample is likely to fall, potentially diluting margin contribution per reaction. If the market responds by increasing volume but not proportionally to offset the lower price, the net effect could be a negative impact on both gross margin and profitability, especially if the shift occurs rapidly across a large customer base. {bullet} Funding uncertainty in the U.S. academic sphere remains a significant risk. Management repeatedly cited “systemic turbulence in research funding dynamics” and “uncertainty around U.S. academic and government funding mechanisms” as persistent headwinds. This volatility has already manifested in a 6 % decline in Americas revenue, and any further erosion of institutional budgets—whether due to federal budget cuts, grant reallocation, or delayed disbursement—could exacerbate the pressure on sales cycles, lower sales velocity, and reduce future consumables revenue, especially for the price‑sensitive single‑cell segment. {bullet} Competitive dynamics in the spatial and single‑cell markets are intensifying. While 10x claims to be well ahead of competitors, the industry landscape includes several players that are accelerating new product releases, such as multiplexed spatial assays and lower‑cost sequencing platforms. If a competitor can deliver comparable performance at a lower total cost of ownership or offer better integration with existing laboratory workflows, customers may shift away from 10x. Management’s acknowledgment of a “price/mix headwind” suggests that the company is aware of potential erosion in market share, yet has not yet articulated a concrete strategy to defend its positioning or accelerate adoption rates. {bullet} The company’s pivot toward clinical diagnostics via its CLIA lab carries high regulatory, operational, and capital risks that are not fully reflected in the current guidance. Building a CLIA‑certified laboratory entails significant upfront investment in equipment, compliance infrastructure, and personnel, and the regulatory approval process can be protracted. Moreover, the clinical market is highly price‑sensitive, with reimbursement frameworks that may not yet favor novel, high‑resolution diagnostic tests. If the company fails to achieve timely regulatory clearance or secure payer coverage, the expected revenue upside could be severely delayed or diminished, undermining the value proposition of this strategic shift. {bullet} The company’s reliance on a few high‑growth projects—such as the “billion‑cell” initiative and the Arc Institute collaboration—creates a concentration risk. These projects, while high profile, involve long‑term data acquisition and may not translate into immediate revenue. If any of these collaborations stall, encounter data quality issues, or fail to meet their scientific objectives, 10x could face reputational damage and lose the opportunity to convert research data into consumables sales. The uncertain outcome of these large‑scale projects introduces a level of risk that is not captured in the financial guidance. {bullet} 10x’s guidance for 2026 reflects a conservative stance, projecting only 0‑4 % growth excluding the $44 million litigation settlement. Such modest growth suggests that the company anticipates a plateau in consumables demand amid constrained funding and cap‑ex. If the market does not provide the anticipated double‑digit consumables growth, the company could see its revenue trajectory flatten, impairing shareholder value and potentially prompting a downward revision of valuation multiples. {bullet} The company’s cost structure may become a liability if the anticipated margin improvement from lower royalty and warranty costs is offset by higher manufacturing expenses. Management noted an increase in manufacturing costs in 2025, driven by the rollout of new assays and increased production volumes. If the manufacturing cost curve continues to steepen—due to raw material price inflation, supply chain disruptions, or the need for additional quality control—margin compression could follow, eroding the benefits gained from the improved gross margin in 2025. {bullet} Cash reserves, while healthy, also present an implicit risk. An overly aggressive investment strategy—such as pursuing additional acquisitions or capital projects—could drain liquidity and reduce the company’s ability to weather unforeseen downturns or to invest in essential R&D when needed. Management has signaled an openness to deploy capital, but the lack of a defined allocation framework introduces uncertainty around how the cash will be used and whether it will be directed toward value‑creating initiatives or potentially dilutive growth tactics. {bullet} Finally, the broader macroeconomic environment—characterized by inflationary pressures, tightening monetary policy, and supply chain constraints—could increase operating costs and compress margins across the life‑science sector. If 10x’s suppliers face higher raw material costs or logistical delays, the company may be forced to pass those costs onto customers, which could dampen demand or erode competitiveness. The company’s current guidance does not appear to account for such escalation risks, leaving a potential gap between expected and actual performance.
Read more

Product and Service Breakdown of Revenue (2025)

Peer comparison

Companies in the Health Information Services
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 GEHC GE HealthCare Technologies Inc. 28.30 Bn 14.85 1.35 10.13 Bn
2 VEEV Veeva Systems Inc 25.58 Bn 28.11 8.01 -
3 BTSG BrightSpring Health Services, Inc. 11.57 Bn 54.88 0.85 2.50 Bn
4 HQY Healthequity, Inc. 7.08 Bn 33.00 5.39 0.96 Bn
5 DOCS Doximity, Inc. 4.41 Bn 18.51 6.91 -
6 WAY Waystar Holding Corp. 3.58 Bn 26.69 3.10 1.47 Bn
7 HNGE Hinge Health, Inc. 2.95 Bn -6.00 5.07 -
8 PRVA Privia Health Group, Inc. 2.76 Bn 118.95 1.30 -